SAT0351 Long-Term Safety and Efficacy of Certolizumab Pegol in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 96-Week Outcomes of the Rapid-Axspa Trial

J Braun,T Nurminen,J Sieper,M Rudwaleit,R Landewé,D Van Der Heijde,B Hoepken,A Deodhar,P.J Mease,M Dougados,W Maksymowych

doi:10.1136/annrheumdis-2014-eular.1636

SAT0351 Long-Term Safety and Efficacy of Certolizumab Pegol in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 96-Week Outcomes of the Rapid-Axspa Trial

J Braun, T Nurminen + Show 9 more

https://doi.org/10.1136/annrheumdis-2014-eular.1636

Copy DOI

Journal: Annals of the Rheumatic Diseases

Publication Date: Jun 1, 2014

Affiliation: Rheumazentrum Ruhrgebiet, UCB Pharma (Germany), Charité - Universitätsmedizin Berlin, Endokrinologikum, Academic Medical Center, Oregon Health & Science University, Swedish Medical Center, Seattle University, University of Washington, Hôpital Cochin, University of Alberta

#Efficacy Of Certolizumab Pegol #Safety Of Certolizumab Pegol + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

BackgroundPrevious reports of RAPID-axSpA (NCT01087762) demonstrated efficacy and safety of certolizumab pegol (CZP) in patients (pts) with axial spondyloarthritis (axSpA) including pts with ankylosing spondylitis (AS) and pts with non-radiographic...

Full Text